Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...
These differences remained significant beyond the initial 90 days, indicating durable diagnostic sensitivity and facilitating earlier, risk-appropriate treatment decisions, which supports broader ...
Role of circulating tumor DNA (ctDNA) in locally advanced (LA) and metastatic urothelial cancer (mUC). Clinical features of patients with malignant lesions detected by BLC only (A) and those with risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results